• BILSKI, A.J., HALLIDAY, S.E., FITZGERALD, J.D. & WALE, J.L. (1983). The pharmacology of a β2-selective adrenoceptor antagonist (ICI 118551). J. Cardiovasc. Pharmacol., 5, 430437.
  • FUKUDA, T., SETOGUCHI, M. & INABA, K. (1991). The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur. J. Pharmacol., 196, 299305.
  • GARCIA, N., JÁRAI, Z., MIRSHAHI, F., KUNOS, G. & SANYAL, A.J. (2001). Systemic and portal hemodynamic effects of anandamide. Am. J. Physiol., 280, G14G20.
  • GARDINER, S.M., KEMP, P.A., BENNETT, T., BOSE, C., FOULKES, R. & HUGHES, B. (1992). Involvement of β2-adrenoceptors in the regional haemodynamic responses to bradykinin in conscious rats. Br. J. Pharmacol., 105, 839848.
  • GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1995). Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br. J. Pharmacol., 116, 20052016.
  • GARDINER, S.M., MARCH, J.E., KEMP, P.A. & BENNETT, T. (2001). Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br. J. Pharmacol., 133, 445453.
  • GARDINER, S.M., MARCH, J.E., KEMP, P.A. & BENNETT, T. (2002a). Effects of the cannabinoid receptor antagonist, AM 251, on the cardiovascular responses to the cannabinoid receptor agonist, WIN 55212-2, and to anandamide, in conscious rats. Br. J. Pharmacol., (in press).
  • GARDINER, S.M., MARCH, J.E., KEMP, P.A. & BENNETT, T. (2002b). β2-adrenoceptor involvement in the hindquarters vasodilator effects of WIN 55212-2, HU 210 and anandamide in conscious Sprague-Dawley rats. Br. J. Pharmacol., (in press).
  • GATLEY, S.J., GIFFORD, A.N., VOLKOW, N.D., LAN, R. & MAKRIYANNIS, A. (1996). 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol., 307, 331338.
  • GATLEY, S.J., LAN, R., PYATT, B., GIFFORD, A.N., VOLKOW, N.D. & MAKRIYANNIS, A. (1997). Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM 251 to rodent brain cannabinoid receptors. Life Sci., 61, PL191PL197.
  • HILLARD, C.J. (2000). Endocannabinoids and vascular function. J. Pharmacol. Exp. Therap., 294, 2732.
  • KUNOS, G., JÁRAI, Z., BÁTKAI, S., GOPARAJU, S.K., ISHAC, E.J.N., LIU, J., WANG, L. & WAGNER, J.A. (2000). Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids, 108, 159168.
  • LAKE, K.D., MARTIN, B.R., KUNOS, G. & VARGA, K. (1997). Cardiovascular effects of anandamide in anesthetised and conscious normotensive and hypertensive rats. Hypertension, 29, 12041210.
  • LIU, B., BENNETT, T. & GARDINER, S.M. (2000). Cardiovascular effects on anandamide and of 5-HT in the absence and presence of the 5HT3-receptor antagonist, azasetron, in conscious rats. Br. J. Pharmacol., 131, 172P.
  • MASUDA, M., MIYASAKA, K. & FUNAKOSHI, A. (1997). Involvement of 5-hydroxytryptamine (5HT)3 receptor mechanisms in regulation of basal pancreatic secretion in conscious rats. J. Auton. Nerv. Syst., 62, 5862.
  • MECHOULAM, R., FRIDE, E. & DI MARZO, V. (1998). Endocannabinoids. Eur. J. Pharmacol., 359, 118.
  • PIOMELLI, D., GIUFFRIDA, A., CALIGNANO, A. & DE FONSECA, R. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci., 21, 218224.
  • STEIN, E.A., FULLER, S.A., EDGEMOND, W.S. & CAMPBELL, W.B. (1996). Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br. J. Pharmacol., 119, 107114.
  • VARGA, K., LAKE, K.D., HUANGFU, D., GUYENET, P.G. & KUNOS, G. (1996). Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension, 28, 682686.
  • VARGA, K., LAKE, K., MARTIN, B.R. & KUNOS, G. (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol., 278, 279283.
  • VEELKEN, R., HILGERS, K.F., SCROGIN, K.E., MANN, J.F.E. & SCHMIEDER, R.E. (1998). Endogenous angiotensin II and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors. Br. J. Pharmacol., 125, 17611767.
  • WAGNER, J.A., JÁRAI, Z., BÁTKAI, S. & KUNOS, G. (2001). Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur. J. Pharmacol., 423, 203210.
  • WIDDOP, R.E., GARDINER, S.M., KEMP, P.A. & BENNETT, T. (1992). The influence of atropine and atenolol on the cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol., 105, 653656.
  • ZHOU, X.F. & LIVETT, B.G. (1991). Capsaicin-sensitive sensory neurons are involved in the plasma-catecholamine response of rats to selective stressors. J. Physiol., 433, 393407.
  • ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SØRGÅD, M., DI MARZO, V., JULIUS, D. & HÖGESTÄTT, E.D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452457.